TRICAPITAL

Sisaltech a natural fiber from the Agave plant, is durable, biodegradable, and has low environmental impact in production. Sisaltech makes the use of these in building insulation a very eco-friendly choice.

Kaly is a seaweed farming company focused on providing nature-based solutions to significant environmental challenges. It operates its own farms to cultivate seaweed, which is processed into biostimulants and serves various industries, including food, animal feed, and fertilizers. Kaly's vertical integration allows it to supply bio-based feedstock for a range of applications, including plastic alternatives, cosmetics, pharmaceuticals, and textiles. The company combines a commitment to sustainability with innovative practices, aiming to address pressing ecological issues while promoting the diverse uses of seaweed.

H2CHP specializes in free piston combined heat and power technology, focusing on the efficient generation of electricity from waste heat. The company aims to optimize fuel energy use through combined heat and power systems, which produce both electrical power and useful heat. H2CHP also offers zero-carbon fuels, allowing clients to harness sustainable energy solutions while reducing environmental impact.

HonuWorx is a technology company specializing in autonomous systems designed to enhance the efficiency and sustainability of robotic operations. The company's innovative software platform utilizes an edge-cloud architecture to facilitate communication and control among geographically distributed stakeholders, enabling them to monitor and manage robotic systems even when they are beyond line-of-sight. HonuWorx develops subsea robotics that support unmanned marine operations, significantly reducing dependence on large, costly manned vessels. By integrating off-the-shelf technologies, the company promotes lean operations and minimizes travel needs for offshore work, thereby aiding industries in restoring, exploring, and sustainably commercializing ocean resources.

ŌGI Bio is a start-up company emerging from The University of Edinburgh, focused on transforming microbial cultivation and management. The company has developed a modular culturing system that aims to replicate traditional manual flask culturing methods. This innovative system consists of a base unit, which can be customized with retrofittable modules that allow users to add or remove features according to their specific measurement and control needs during the culturing process. By offering this flexible approach, ŌGI Bio seeks to enhance the efficiency and effectiveness of microbial research and applications.

Heero Technologies is a company that focuses on enhancing energy efficiency in residential properties. It provides a comprehensive platform that simplifies the energy retrofit process for homeowners, offering personalized recommendations to improve home energy performance. The company addresses common challenges associated with energy retrofits, such as the disruption caused by invasive measures and the complexities of financing options. By enabling lenders and installers to better differentiate their services, Heero Technologies facilitates the adoption of renewable technologies in privately owned homes, ultimately aiming to reduce emissions and create a more streamlined user experience in energy improvements.

Glen Clova Scientific is focused on developing a new generation of active biological drugs that aim to create natural antibodies against harmful targets. These innovative drugs are designed to improve the treatment of chronic diseases by minimizing the need for safety monitoring and reducing the frequency of dosing. As a result, patients benefit from a more cost-effective treatment approach, while the company also seeks to address healthcare challenges in markets with limited infrastructure.

Carcinotech is transforming cancer research through the innovative production of 3D-printed micro-tumours derived from patient biopsies, primary cells, immune cells, and cancer stem cells. This technology facilitates rapid, ethical, and precise drug screening as well as pre-clinical and personalized medicine testing. By leveraging tissue engineering and advanced robotic manufacturing, Carcinotech creates highly predictive, assay-ready tumours that reflect the unique cancer heterogeneity of individual patients. This approach aims to enhance the drug screening process and expedite the development of more effective cancer treatments. Collaborating with global partners, including leading pharmaceutical companies, surgeons, pathologists, and clinicians, Carcinotech is dedicated to advancing oncology drug development and improving treatment outcomes for cancer patients, ultimately increasing their chances of survival.

SellmyArtworks is to buy and sell pre-loved artwork in a simple, fast, and affordable way like no other pre-owned art seller.

Aurum Biosciences Ltd is a pharmaceutical company based in Glasgow, United Kingdom, specializing in the development of innovative treatments for various clinical conditions with significant unmet medical needs. Founded in 2010, the company is focused on its lead product, ABL101, which is aimed at managing acute ischaemic stroke. This product incorporates a unique perfluorocarbon technology that carries oxygen to organs and tissues, independent of hemoglobin levels. Aurum also utilizes proprietary image analysis software in conjunction with magnetic resonance imaging to enhance the assessment of stroke patients. The company is in the final stages of preclinical development and plans to initiate clinical studies to evaluate the efficacy and safety of ABL101 soon. Additionally, Aurum is exploring follow-on programs targeting heart disease, cancer, epilepsy, and dementia, demonstrating its commitment to addressing diverse health challenges.

Beta Bugs is an insect genetics company focused on developing high-performance breeds of Black Soldier Fly for insect farmers. The company's primary mission is to enhance the productivity of the insect protein sector, making it competitive with traditional feed ingredients such as fishmeal and soymeal. To achieve this, Beta Bugs operates a breeding program called HiPer-Fly® and runs an egg production site known as The Multiplier®, supplying its breeds to both UK and international markets. By leveraging biotechnology and breeding techniques, Beta Bugs aims to establish a sustainable protein source that converts food waste into high-quality protein for use in livestock, aquaculture, and pet feed, thereby providing an alternative to conventional feed sources. The company is headquartered at the Easter Bush Campus, collaborating with the Roslin Institute, a leader in animal genetics.

Heero Technologies is a company that focuses on enhancing energy efficiency in residential properties. It provides a comprehensive platform that simplifies the energy retrofit process for homeowners, offering personalized recommendations to improve home energy performance. The company addresses common challenges associated with energy retrofits, such as the disruption caused by invasive measures and the complexities of financing options. By enabling lenders and installers to better differentiate their services, Heero Technologies facilitates the adoption of renewable technologies in privately owned homes, ultimately aiming to reduce emissions and create a more streamlined user experience in energy improvements.

Heero Technologies is a company that focuses on enhancing energy efficiency in residential properties. It provides a comprehensive platform that simplifies the energy retrofit process for homeowners, offering personalized recommendations to improve home energy performance. The company addresses common challenges associated with energy retrofits, such as the disruption caused by invasive measures and the complexities of financing options. By enabling lenders and installers to better differentiate their services, Heero Technologies facilitates the adoption of renewable technologies in privately owned homes, ultimately aiming to reduce emissions and create a more streamlined user experience in energy improvements.

Aveni is an award-winning FinTech company, dedicated to enhancing human expertise and efficiency through advanced AI technology. Specialising in Natural language Processing (NLP) and AI automation, Aveni provides tailored solutions that empower financial services businesses to achieve remarkable efficiency while maintaining the highest standards of service. Their flagship products, Aveni Detect and Aveni Assist, are purpose-built to streamline workflows, automate administrative tasks, and improve quality assurance processes, ultimately driving a productivity revolution in the industry.

ŌGI Bio is a start-up company emerging from The University of Edinburgh, focused on transforming microbial cultivation and management. The company has developed a modular culturing system that aims to replicate traditional manual flask culturing methods. This innovative system consists of a base unit, which can be customized with retrofittable modules that allow users to add or remove features according to their specific measurement and control needs during the culturing process. By offering this flexible approach, ŌGI Bio seeks to enhance the efficiency and effectiveness of microbial research and applications.

Carcinotech is transforming cancer research through the innovative production of 3D-printed micro-tumours derived from patient biopsies, primary cells, immune cells, and cancer stem cells. This technology facilitates rapid, ethical, and precise drug screening as well as pre-clinical and personalized medicine testing. By leveraging tissue engineering and advanced robotic manufacturing, Carcinotech creates highly predictive, assay-ready tumours that reflect the unique cancer heterogeneity of individual patients. This approach aims to enhance the drug screening process and expedite the development of more effective cancer treatments. Collaborating with global partners, including leading pharmaceutical companies, surgeons, pathologists, and clinicians, Carcinotech is dedicated to advancing oncology drug development and improving treatment outcomes for cancer patients, ultimately increasing their chances of survival.

Aveni is an award-winning FinTech company, dedicated to enhancing human expertise and efficiency through advanced AI technology. Specialising in Natural language Processing (NLP) and AI automation, Aveni provides tailored solutions that empower financial services businesses to achieve remarkable efficiency while maintaining the highest standards of service. Their flagship products, Aveni Detect and Aveni Assist, are purpose-built to streamline workflows, automate administrative tasks, and improve quality assurance processes, ultimately driving a productivity revolution in the industry.

Aurum Biosciences Ltd is a pharmaceutical company based in Glasgow, United Kingdom, specializing in the development of innovative treatments for various clinical conditions with significant unmet medical needs. Founded in 2010, the company is focused on its lead product, ABL101, which is aimed at managing acute ischaemic stroke. This product incorporates a unique perfluorocarbon technology that carries oxygen to organs and tissues, independent of hemoglobin levels. Aurum also utilizes proprietary image analysis software in conjunction with magnetic resonance imaging to enhance the assessment of stroke patients. The company is in the final stages of preclinical development and plans to initiate clinical studies to evaluate the efficacy and safety of ABL101 soon. Additionally, Aurum is exploring follow-on programs targeting heart disease, cancer, epilepsy, and dementia, demonstrating its commitment to addressing diverse health challenges.

Aveni is an award-winning FinTech company, dedicated to enhancing human expertise and efficiency through advanced AI technology. Specialising in Natural language Processing (NLP) and AI automation, Aveni provides tailored solutions that empower financial services businesses to achieve remarkable efficiency while maintaining the highest standards of service. Their flagship products, Aveni Detect and Aveni Assist, are purpose-built to streamline workflows, automate administrative tasks, and improve quality assurance processes, ultimately driving a productivity revolution in the industry.

MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, specializing in the development of a new class of anti-infective medicines derived from minor groove binder compounds. Established in 2009, the company focuses on creating small molecules with specific antibacterial properties to combat both multi-resistant and susceptible Gram-positive bacteria. One of its key products, MGB-BP-3, is an antibacterial agent designed for the oral treatment of Clostridium difficile-associated disease. MGB Biopharma aims to address the challenges of antibiotic resistance by employing a novel mode of action that targets bacteria lacking inherent resistance mechanisms, offering a promising approach to treating bacterial infections effectively.

MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, specializing in the development of a new class of anti-infective medicines derived from minor groove binder compounds. Established in 2009, the company focuses on creating small molecules with specific antibacterial properties to combat both multi-resistant and susceptible Gram-positive bacteria. One of its key products, MGB-BP-3, is an antibacterial agent designed for the oral treatment of Clostridium difficile-associated disease. MGB Biopharma aims to address the challenges of antibiotic resistance by employing a novel mode of action that targets bacteria lacking inherent resistance mechanisms, offering a promising approach to treating bacterial infections effectively.

Blue Square Utilities Ltd is an independent smart meter installation company based in Newcastle upon Tyne, United Kingdom, serving small to medium-sized energy suppliers across the UK. Established in 2017, the company specializes in the installation and maintenance of both legacy and commercial metering services. Blue Square Utilities offers a comprehensive range of services, including data management and control, scheduling, customer interaction, and asset management. Additionally, the company provides accredited meter operator and meter asset manager services. With a team of fully qualified engineers registered with Energy & Utility Skills, Blue Square Utilities is well-equipped to deliver end-to-end dual fuel smart meter installation solutions, drawing on extensive experience from the Smart Metering Rollout.

MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, specializing in the development of a new class of anti-infective medicines derived from minor groove binder compounds. Established in 2009, the company focuses on creating small molecules with specific antibacterial properties to combat both multi-resistant and susceptible Gram-positive bacteria. One of its key products, MGB-BP-3, is an antibacterial agent designed for the oral treatment of Clostridium difficile-associated disease. MGB Biopharma aims to address the challenges of antibiotic resistance by employing a novel mode of action that targets bacteria lacking inherent resistance mechanisms, offering a promising approach to treating bacterial infections effectively.

FINDRA is a Scottish brand that specializes in high-performance outdoor and adventure clothing for women. The company focuses on designing stylish, versatile, and sustainable apparel made from Italian sports merino wool, which offers natural moisture-wicking properties. FINDRA's mission is to inspire women to embrace an active lifestyle and explore the outdoors without sacrificing performance or style. Operating through an e-commerce platform, the brand aims to encourage consumers to engage in healthy adventures and enhance their well-being.

My1Login offers a cloud-based password management and identity access management solution aimed at enhancing cybersecurity for enterprises. Founded in 2007 and headquartered in Glasgow, with additional offices in Palo Alto and London, the company provides a secure vault for storing passwords, online bookmarks, and other personal information like bank details and emergency contacts. My1Login's platform addresses common challenges such as identity sprawl, password fatigue, and compliance issues by providing a single user identity for employees. This next-generation solution integrates with various identity standards, including SAML and OAuth 2.0, and can connect with legacy systems lacking existing connectors. By enabling control over user identity and access across cloud, mobile, and desktop environments, My1Login helps organizations improve productivity while mitigating security threats and achieving compliance.

Aurum Biosciences Ltd is a pharmaceutical company based in Glasgow, United Kingdom, specializing in the development of innovative treatments for various clinical conditions with significant unmet medical needs. Founded in 2010, the company is focused on its lead product, ABL101, which is aimed at managing acute ischaemic stroke. This product incorporates a unique perfluorocarbon technology that carries oxygen to organs and tissues, independent of hemoglobin levels. Aurum also utilizes proprietary image analysis software in conjunction with magnetic resonance imaging to enhance the assessment of stroke patients. The company is in the final stages of preclinical development and plans to initiate clinical studies to evaluate the efficacy and safety of ABL101 soon. Additionally, Aurum is exploring follow-on programs targeting heart disease, cancer, epilepsy, and dementia, demonstrating its commitment to addressing diverse health challenges.

My1Login offers a cloud-based password management and identity access management solution aimed at enhancing cybersecurity for enterprises. Founded in 2007 and headquartered in Glasgow, with additional offices in Palo Alto and London, the company provides a secure vault for storing passwords, online bookmarks, and other personal information like bank details and emergency contacts. My1Login's platform addresses common challenges such as identity sprawl, password fatigue, and compliance issues by providing a single user identity for employees. This next-generation solution integrates with various identity standards, including SAML and OAuth 2.0, and can connect with legacy systems lacking existing connectors. By enabling control over user identity and access across cloud, mobile, and desktop environments, My1Login helps organizations improve productivity while mitigating security threats and achieving compliance.

Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, focused on developing and commercializing medical devices and pharmaceuticals that leverage mimetics of extra-alveolar lamellar bodies. The company offers Lamellasomes, a synthetic product designed to replicate the functions of lamellar bodies, primarily targeting respiratory diseases such as cystic fibrosis, as well as conditions like dry eye disease and radiotherapy-induced xerostomia. Established in June 2007, Lamellar Biomedical acquired the intellectual property rights to this innovative technology, which aims to improve treatment outcomes through anti-infective properties that enhance antibiotic efficacy and facilitate the delivery of genetic material for pulmonary disease therapies. The company's efforts are directed towards providing transformative solutions for complex and rare respiratory conditions.

My1Login offers a cloud-based password management and identity access management solution aimed at enhancing cybersecurity for enterprises. Founded in 2007 and headquartered in Glasgow, with additional offices in Palo Alto and London, the company provides a secure vault for storing passwords, online bookmarks, and other personal information like bank details and emergency contacts. My1Login's platform addresses common challenges such as identity sprawl, password fatigue, and compliance issues by providing a single user identity for employees. This next-generation solution integrates with various identity standards, including SAML and OAuth 2.0, and can connect with legacy systems lacking existing connectors. By enabling control over user identity and access across cloud, mobile, and desktop environments, My1Login helps organizations improve productivity while mitigating security threats and achieving compliance.

MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, specializing in the development of a new class of anti-infective medicines derived from minor groove binder compounds. Established in 2009, the company focuses on creating small molecules with specific antibacterial properties to combat both multi-resistant and susceptible Gram-positive bacteria. One of its key products, MGB-BP-3, is an antibacterial agent designed for the oral treatment of Clostridium difficile-associated disease. MGB Biopharma aims to address the challenges of antibiotic resistance by employing a novel mode of action that targets bacteria lacking inherent resistance mechanisms, offering a promising approach to treating bacterial infections effectively.

Fios Genomics Ltd. is a bioinformatics company based in Edinburgh, UK, specializing in data analysis services for the pharmaceutical, biotech, and academic sectors worldwide. Founded in 2008 as a spinout from the University of Edinburgh, Fios Genomics offers a comprehensive suite of services, including microarray analysis, next-generation sequencing, proteomics, and metabolomics. Its capabilities extend to biomarker identification, gene expression analysis, and experimental design, allowing clients to leverage genomic, transcriptomic, and proteomic data through tailored workflows. The company serves a diverse clientele, including major pharmaceutical firms, clinical centers, and research institutions across Europe, the United States, and Asia, supporting applications in pre-clinical and clinical development, drug repurposing, and stratified medicine.

Fios Genomics Ltd. is a bioinformatics company based in Edinburgh, UK, specializing in data analysis services for the pharmaceutical, biotech, and academic sectors worldwide. Founded in 2008 as a spinout from the University of Edinburgh, Fios Genomics offers a comprehensive suite of services, including microarray analysis, next-generation sequencing, proteomics, and metabolomics. Its capabilities extend to biomarker identification, gene expression analysis, and experimental design, allowing clients to leverage genomic, transcriptomic, and proteomic data through tailored workflows. The company serves a diverse clientele, including major pharmaceutical firms, clinical centers, and research institutions across Europe, the United States, and Asia, supporting applications in pre-clinical and clinical development, drug repurposing, and stratified medicine.

The complexity and breadth of online media has reached a level where it is virtually impossible to manage your online marketing without clever software to help you. 4th aspect provides marketing professionals with tools that: measure, optimize and promote your content in virtually any form, across multiple content platforms and allows your marketing team to engage with advocates, influencers and of course customers. 4th aspect frees up your marketing resources and allows your team to create the content that your audience really cares about. Promote your brand on a global scale, while reducing costs and increasing control. Place your Brand ahead of your competitors and in front of your customers!

My1Login offers a cloud-based password management and identity access management solution aimed at enhancing cybersecurity for enterprises. Founded in 2007 and headquartered in Glasgow, with additional offices in Palo Alto and London, the company provides a secure vault for storing passwords, online bookmarks, and other personal information like bank details and emergency contacts. My1Login's platform addresses common challenges such as identity sprawl, password fatigue, and compliance issues by providing a single user identity for employees. This next-generation solution integrates with various identity standards, including SAML and OAuth 2.0, and can connect with legacy systems lacking existing connectors. By enabling control over user identity and access across cloud, mobile, and desktop environments, My1Login helps organizations improve productivity while mitigating security threats and achieving compliance.

Smart Compliance Ltd, founded in 2010 by Scott Wallace and Billy Mitchell, specializes in developing advanced gas monitoring devices that enhance safety in residential and commercial properties. The company's technology enables landlords to monitor the presence of hazardous gases, such as carbon monoxide, smoke, and natural gas, without needing direct access to the property. This innovative detector captures and communicates data to alert individuals both inside and outside the building about potential dangers, facilitating compliance with health and safety standards. By providing reliable information about gas threats, Smart Compliance supports landlords, tenants, and real estate agents in maintaining a safe living environment.

Inquisitive Systems is an Edinburgh based company with ambition to rapidly become a world leader in building information security software. Inquisitive Systems is a spin-out from Edinburgh Napier University. The Company started trading in September 2010 after being founded by Dr Jamie Graves and Prof Bill Buchanan in 2008. The core company IP, foxDNATM (part of the ZoneFox product), was developed by Dr Graves during a post-graduate project into an improved system for digital forensic investigations. After successfully securing a Scottish Enterprise Proof of Concept grant, the company developed the foxDNATM technology for commercial deployment.

Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, focused on developing and commercializing medical devices and pharmaceuticals that leverage mimetics of extra-alveolar lamellar bodies. The company offers Lamellasomes, a synthetic product designed to replicate the functions of lamellar bodies, primarily targeting respiratory diseases such as cystic fibrosis, as well as conditions like dry eye disease and radiotherapy-induced xerostomia. Established in June 2007, Lamellar Biomedical acquired the intellectual property rights to this innovative technology, which aims to improve treatment outcomes through anti-infective properties that enhance antibiotic efficacy and facilitate the delivery of genetic material for pulmonary disease therapies. The company's efforts are directed towards providing transformative solutions for complex and rare respiratory conditions.

pureLiFi Ltd. is a light communications technology company based in Edinburgh, United Kingdom, specializing in Li-Fi, a visible light communications technology that utilizes the visible light spectrum for wireless data transmission. Founded in 2012, pureLiFi develops various products, including the Li-1st platform for testing VLC applications and Li-Flame solutions that enhance network security by preventing external intrusions. The company also offers the Li-Fire Platform, along with ceiling and desktop units, and LiFi-XC devices that provide secure wireless communications compatible with multiple operating systems. Its innovative technology addresses the challenges of diminishing wireless capacity, serving applications across diverse sectors such as healthcare, aviation, and transportation. By converting light into electrical signals, pureLiFi enables high-density data transmission, presenting a viable alternative to traditional Wi-Fi.

Blackford Analysis Ltd. specializes in software solutions that enhance the comparison of medical images, thereby saving clinicians time and improving productivity in healthcare settings. Founded in 2010 and based in Edinburgh, the company offers products such as the Blackford Workflow Server, which integrates into hospital IT frameworks, and the Blackford Smart Localizer, designed for seamless comparison of imaging studies within existing systems. These tools enable users to conduct comparisons with a single click, typically resulting in time savings of 10% to 20%. Blackford’s technology employs advanced algorithms and multi-core processing to facilitate rapid registration of scans from various sources. The company partners with multiple imaging system providers and has expanded its reach by collaborating with organizations outside diagnostic imaging to enhance their offerings. Blackford Analysis has experienced significant growth, with sales offices in both the UK and the United States, and continues to develop bespoke image processing solutions to meet diverse healthcare needs.

Syntropharma is an emerging pharmaceutical company focussed on taking commercially successful generic compounds and improving their clinical profile by reformulating them as patch applications which are applied to the skin. Its vision is to develop a stream of first and second to market transdermal products with strong IP that will be out-licensed to pharmaceutical company partners.

Fios Genomics Ltd. is a bioinformatics company based in Edinburgh, UK, specializing in data analysis services for the pharmaceutical, biotech, and academic sectors worldwide. Founded in 2008 as a spinout from the University of Edinburgh, Fios Genomics offers a comprehensive suite of services, including microarray analysis, next-generation sequencing, proteomics, and metabolomics. Its capabilities extend to biomarker identification, gene expression analysis, and experimental design, allowing clients to leverage genomic, transcriptomic, and proteomic data through tailored workflows. The company serves a diverse clientele, including major pharmaceutical firms, clinical centers, and research institutions across Europe, the United States, and Asia, supporting applications in pre-clinical and clinical development, drug repurposing, and stratified medicine.

Design LED Products Ltd. specializes in the design and manufacturing of innovative lighting solutions, including LED lighting tiles and various backlighting products. The company uses advanced optical resins and films to create a range of products, such as shelf luminaires for product illumination and signage that features both convex and concave designs. Operating under several brands, including Edinburgh and Ness, Design LED serves multiple sectors, including architectural, retail, and automotive applications. Since its incorporation in 2003, the company has focused on delivering energy-efficient, differentiated lighting options to meet the growing global demand for sustainable lighting solutions. With a commitment to transforming the approach to lighting products, Design LED Products aims to be a leader in the rapidly expanding international lighting market.

Sphinx Medical Ltd. is a company located in Bellshill, Scotland, United Kingdom. It develops the artificial sphincter Flow-Secure, which has been sold in Europe for 9 years. It is an innovative device that enables the treatment of severe Male Urinary Incontinence.

IRT Surveys Limited is an infrared thermal imaging company based in Dundee, United Kingdom, that specializes in non-destructive testing and diagnosis of building defects and energy inefficiencies. Founded in 2002, the company offers a range of services including thermal imaging, infrared building surveys, energy audits, air leakage detection, and electronic leak detection. Additionally, it provides energy performance certificates and maintenance planning services. IRT Surveys focuses on rapid analysis and quantification of infrared images, utilizing proprietary software to assess energy loss effectively, helping clients identify issues and plan for improvements in energy efficiency and property condition.

Actual Analytics Limited specializes in behavior analysis solutions for scientific research, focusing on the automatic monitoring of laboratory animals. The company offers products such as ActualTrack, which tracks the movement of various species like rodents and zebrafish via video analysis, and Actual Home Cage Analysis (ActualHCA), which facilitates non-invasive data collection and automated behavioral analysis of group-housed rodents. By utilizing advanced video analysis technology, Actual Analytics enables researchers to streamline the drug discovery process, particularly for treatments related to Central Nervous System diseases such as Alzheimer’s and Parkinson’s. This automation not only enhances accuracy but also reduces costs associated with traditional manual tracking methods. Founded in 2009 and headquartered in Edinburgh, UK, Actual Analytics distributes its tools in several countries, including the United States, Spain, Taiwan, China, and Germany.

MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, specializing in the development of a new class of anti-infective medicines derived from minor groove binder compounds. Established in 2009, the company focuses on creating small molecules with specific antibacterial properties to combat both multi-resistant and susceptible Gram-positive bacteria. One of its key products, MGB-BP-3, is an antibacterial agent designed for the oral treatment of Clostridium difficile-associated disease. MGB Biopharma aims to address the challenges of antibiotic resistance by employing a novel mode of action that targets bacteria lacking inherent resistance mechanisms, offering a promising approach to treating bacterial infections effectively.

Syntropharma is an emerging pharmaceutical company focussed on taking commercially successful generic compounds and improving their clinical profile by reformulating them as patch applications which are applied to the skin. Its vision is to develop a stream of first and second to market transdermal products with strong IP that will be out-licensed to pharmaceutical company partners.

IRT Surveys Limited is an infrared thermal imaging company based in Dundee, United Kingdom, that specializes in non-destructive testing and diagnosis of building defects and energy inefficiencies. Founded in 2002, the company offers a range of services including thermal imaging, infrared building surveys, energy audits, air leakage detection, and electronic leak detection. Additionally, it provides energy performance certificates and maintenance planning services. IRT Surveys focuses on rapid analysis and quantification of infrared images, utilizing proprietary software to assess energy loss effectively, helping clients identify issues and plan for improvements in energy efficiency and property condition.

Antoxis Limited is a pre-clinical drug discovery company based in Aberdeen, United Kingdom, founded in 2005. The company develops a drug discovery platform using its patented Kromex chemistry scaffold, which enables the generation of New Chemical Entities (NCE) aimed at addressing high-value clinical indications. This innovative scaffold, grounded in free radical biology and redox chemistry, protects a vast library of compounds that have the potential to modulate diseases associated with oxidative stress and mitochondrial dysfunction. Antoxis focuses on a subset of Kromex compounds that demonstrate rapid mitochondrial targeting, potent activity, and long-term stability. The company has two main drug families: Proxison, which is designed to enhance the effectiveness of regenerative medicine therapies and is also being explored for neurodegenerative diseases, and Oncamex, a mitochondrial redox modulator developed for co-therapy in drug-resistant cancer, which shows synergy with various cancer treatments.

Exterity has been delivering enterprise-class building IPTV solutions since 2001, and today its products are used in 29 countries by more than 1000 customers, including some of the world's largest corporations. Exterity products enable organizations to distribute broadcast-quality digital TV and video over building or campus IP networks (LANs) to a virtually unlimited number of users, with centralized management, configuration, and control.

Biopta Ltd. is a contract research organization that specializes in providing services to the pharmaceutical industry using functional human tissue. Founded in 2002 and based in Glasgow, United Kingdom, Biopta utilizes ethically donated residual human tissue from surgical procedures to predict drug activity prior to clinical trials. The company offers a range of services, including laboratory techniques, comparative pharmacology, clinical biopsies, and customized solutions. Its expertise encompasses various areas such as cardiac, vascular, respiratory, gastrointestinal, human absorption, skin, and genitourinary research. Additionally, Biopta maintains a catalogue of human functional tissue assays that includes standard assays for diverse applications. The company operates laboratories in Glasgow and Maryland and has been a subsidiary of ReproCELL, Inc. since December 2015.

Syntropharma is an emerging pharmaceutical company focussed on taking commercially successful generic compounds and improving their clinical profile by reformulating them as patch applications which are applied to the skin. Its vision is to develop a stream of first and second to market transdermal products with strong IP that will be out-licensed to pharmaceutical company partners.

Founded in 2003 by Graeme Bryce and Dave Reynolds, Factonomy licenses its technology framework to companies to help them reduce the time and cost it takes to develop applications. Factonomy's agile software environment enables the rapid development of web-enabled business applications using declarative XML only. Unlike other development platforms, the Factonomy Framework allows developers to work independently on functionality, content and style, providing a coherent end-to-end environment so they can deliver solutions which are flexible and cost effective.

PowerPhotonic Limited specializes in the design and manufacturing of precision micro-optics for various applications, including laser projection systems, optical telecommunications, and industrial materials processing. The company offers a diverse range of products, such as high-powered diode laser optics, microlens arrays, beam shapers, and refractive diffusers. Additionally, PowerPhotonic provides design and prototyping services to cater to specific customer needs. Founded in 2004, the company is headquartered in Dalgety Bay, United Kingdom, with operational reach extending to North America and Southeast Asia. Their micro-optical fabrication technology enables clients to access a comprehensive selection of standard and custom optical solutions, enhancing the performance of laser systems across multiple sectors.

Touch Bionics Inc., is a Livingston, Scotland, UK-based developer of advanced upper-limb prosthetics.

Antoxis Limited is a pre-clinical drug discovery company based in Aberdeen, United Kingdom, founded in 2005. The company develops a drug discovery platform using its patented Kromex chemistry scaffold, which enables the generation of New Chemical Entities (NCE) aimed at addressing high-value clinical indications. This innovative scaffold, grounded in free radical biology and redox chemistry, protects a vast library of compounds that have the potential to modulate diseases associated with oxidative stress and mitochondrial dysfunction. Antoxis focuses on a subset of Kromex compounds that demonstrate rapid mitochondrial targeting, potent activity, and long-term stability. The company has two main drug families: Proxison, which is designed to enhance the effectiveness of regenerative medicine therapies and is also being explored for neurodegenerative diseases, and Oncamex, a mitochondrial redox modulator developed for co-therapy in drug-resistant cancer, which shows synergy with various cancer treatments.

Syntropharma is an emerging pharmaceutical company focussed on taking commercially successful generic compounds and improving their clinical profile by reformulating them as patch applications which are applied to the skin. Its vision is to develop a stream of first and second to market transdermal products with strong IP that will be out-licensed to pharmaceutical company partners.

Gas Sensing Solutions Ltd. specializes in the manufacture of carbon dioxide (CO2) sensors, utilizing innovative technology to serve various markets. The company offers a range of products, including COZIR Ambient sensors designed for building control, horticulture, and educational applications, as well as COZIR Wide Range sensors intended for process control in fields such as diving, industrial safety, and automotive. Additionally, the SprintIR sensor is developed for high-speed CO2 measurement in analytical instrumentation and metabolic assessment. Founded in 2005 and headquartered in Glasgow, United Kingdom, Gas Sensing Solutions also provides tailored hardware and software development services to meet specific client needs.